To investigate the utility of new wide-field optical coherence tomography (OCT) device in the evaluation of mid and far retinal periphery and to show its feasibility and advantages in clinical practice.
Consecutive patients underwent a complete ophthalmologic examination including standard OCT and new prototype OCT2 derived from Heidelberg Spectralis.
Thirty-one eyes of 31 patients were studied with a total of 44 lesions, including 18 retinal detachments, 15 retinal holes and tears, 9 retinoschisis, and 2 retinal tufts. Fourteen (32%) lesions were found in mid and 30 (68%) in far periphery with 9 (20%) lesions in the superior region, 10 (23%) in the superior temporal, 8 (18%) in the temporal, 4 (9%) in the inferior temporal, 7 (16%) in the inferior, 4 (9%) in the nasal, and 2 (5%) in the superior nasal. Among the lesions evaluated by OCT2, 10 (71%) in mid periphery and 11 (37%) in far periphery could be imaged by standard OCT.
The introduction of OCT2 into clinical practice may provide significant benefits for imaging peripheral retinal disorders. The application of OCT2 technology with 55° lens and scan length and angle modulation could improve our understanding of peripheral vitreoretinal disorders and facilitate their management.
The authors evaluated the ability of new wide-field optical coherence tomography to evaluate patients with peripheral vitreoretinal pathology. The authors found that optical coherence tomography 2 provides significant benefits for imaging of peripheral retinal disorders also allowing for high-resolution imaging of vitreoretinal interface, retina, and choroid with impact on both clinical and surgical care.
Department of Biomedical and Clinical Science “Luigi Sacco,” Eye Clinic, Sacco Hospital, University of Milan, Milan, Italy.
Reprint requests: Federico Corvi, MD, Department of Biomedical and Clinical Science “Luigi Sacco,” Eye Clinic, Sacco Hospital, University of Milan, Via G.B Grassi 74, 20157 Milan, Italy; e-mail: firstname.lastname@example.org
M. Pellegrini received lecture fees from Optovue Inc. G. Staurenghi received grants and personal fees from Optovue Inc, Heidelberg Engineering, Zeiss Meditec, Nidek, and Centervue. The remaining authors have no financial/conflicting of interests to disclose.
M.G. Cereda and F. Corvi have contributed equally to this study and should be considered as equivalent authors.